Comparative Pharmacology
Head-to-head clinical analysis: LOFEXIDINE HYDROCHLORIDE versus LUMIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOFEXIDINE HYDROCHLORIDE versus LUMIFY.
LOFEXIDINE HYDROCHLORIDE vs LUMIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces central sympathetic outflow by binding to presynaptic alpha-2 receptors in the brainstem, decreasing norepinephrine release.
Selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness.
0.2 mg orally twice daily, titrate by 0.2-0.4 mg/day every 1-2 days to maximum 2.4 mg/day in divided doses.
Instill 1 drop in the affected eye(s) every 6 to 8 hours as needed, not to exceed 4 drops per eye per day.
None Documented
None Documented
Terminal elimination half-life is 11-13 hours in patients with normal renal function; prolonged to up to 40 hours in renal impairment.
Approximately 2.5-3 hours (terminal) in adults; clinical context: duration of mydriasis may be shorter than half-life due to receptor binding.
Primarily renal (approximately 80-90% as unchanged drug and metabolites, with 20-30% unchanged); minor fecal excretion (<5%).
Primarily renal (60-70% unchanged), with biliary/fecal elimination accounting for the remainder.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist